[ILS-WE-02] Lunch Seminar 2: Towards a deeper understanding of wet AMD therapy: optimizing benefits, managing risks and individualizing care
- Apr 02 (Wed)
- 12:15 - 13:15
- Room 17 - Imperial Hotel 2F Peacock (East)
- Novartis Pharma AG
- Retina, Vitreous body
- Chair）Masahito Ohji
- The incidence of blindness due to wet age-related macular degeneration (AMD) has reduced considerably since the introduction of anti-VEGF agents, notably ranibizumab. Building on this success requires a deeper understanding of wet AMD pathology. This in turn can provide insights into how variation between individual patients can lead to differences in their risk of developing the disease as well as their responses to treatment. In order to minimize risk and maximize vision outcomes, the choice of wet AMD therapy should be defined by efficacy, safety and dosing strategy, according to the individual needs of the patient.